Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75p -0.46% 161.25p 162.50p 164.50p 167.00p 162.00p 163.50p 556,195 16:35:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -6.3 -4.5 - 213.69

Immupharma (IMM) Latest News

More Immupharma News
Immupharma Takeover Rumours

Immupharma (IMM) Share Charts

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Intraday Immupharma Chart

Intraday Immupharma Chart

Immupharma (IMM) Discussions and Chat

Immupharma Forums and Chat

Date Time Title Posts
16/12/201722:02IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES7,537
05/12/201718:32ImmuPharma - Global Potential Blockbusters & Huge Potential Upside77
09/10/201707:08Sell order-
07/10/201710:31exciting times -
24/12/201619:50IMM Bullish chart!3

Add a New Thread

Immupharma (IMM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

DateSubject
16/12/2017
08:20
Immupharma Daily Update: Immupharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 162p.
Immupharma has a 4 week average price of 95.75p and a 12 week average price of 49.50p.
The 1 year high share price is 175p while the 1 year low share price is currently 37.75p.
There are currently 132,522,985 shares in issue and the average daily traded volume is 1,050,658 shares. The market capitalisation of Immupharma is £213,693,313.31.
12/12/2017
15:51
hottingup: There is a small pull back on every rise but the rise is now the trend. On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40. To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects and being cheaper to produce, than Benlysta; use in other indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications. Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40. N.B. Lupuzor Symposium 8th June 2016 - 3:35 pm 41 min 40 sec onwards - hTTps://player.vimeo.com/video/170358317 Data from IMM suggests Lupuzor / P140 may be able to treat several blockbuster autoimmune and non-autoimmune diseases, including: - Systemic Lupus Erythematosus (SLE) (Market size $4 bn) (SLE ends Phase 3, Q1 2018) - Neuropsychiatric lupus (NPSLE) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Rheumatoid Arthritis (Market size $28.5 bn by 2025) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022) - Guillan-Barre disease - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Asthma (Market size $20.7 bn in 2015) Other potential evaluations: - Scleroderma (Systemic Sclerosis, Raynaud) - Psoriasis - Multiple Sclerosis (MS) (Market size $20 bn by 2024) Negative preclinical results for potential re-evaluation: - Type I Diabetes (Market size $43 bn by 2021) - Amytrophic Lateral Sclerosis (ALS)
12/12/2017
14:49
top tips: Shares magazine Why the drug space is looking more attractive Shares in parts of the sector are rising and there is a rich stream of news flow in the coming months Thur 26 Oct 2017 Author: Lisa-Marie Janes hTTps://www.youinvest.co.uk/sharesmagazine/2017-10-26/why-the-drug-space-is-looking-more-attractive It has been a volatile few years for the healthcare industry with several headwinds acting as a drag on performance, including the threat of drug pricing caps and healthcare reform in the US. Is life now getting better? The NASDAQ Biotech index in early October traded at its highest level since December 2015. On the UK stock market, shares in many drug makers have been in a rising trend since late summer 2017. Panmure Gordon has even upgraded its stance on the pharmaceuticals, biotechnology and healthcare sector to ‘positive’, believing the next nine months to be a strong period for UK life science company news. ‘Multiple significant trial readouts are expected, companies are generally well funded and many of the headwinds seen in previous quarters are easing,’ says analyst Julie Simmonds. Trump turns attention to tax Simmonds believes many headwinds that dragged on the performance of the overall sector such as the attempt to repeal the Affordable Care Act in the US and drug pricing pressures are easing. ‘Healthcare reform in the US is moving to the back burner to be replaced by tax reform, which could have a more positive outcome for the sector,’ says the analyst. The pressure on pharmaceutical companies to cut drug prices has receded as an immediate threat, but Simmonds flags companies will need to remain conscious on prices at launch and if they choose to hike prices. This could lead to a more imaginative approach to pricing such as patients not paying if the drug is not effective within a specific time period. What's happening with UK-listed drug companies? Simmonds believes ‘rapidly moving technologies’ are behind the positive performance of parts of the UK quoted healthcare sector, pointing to upcoming Phase III results from firms such as ImmuPharma (IMM:AIM). ImmuPharma is undergoing its Phase III trial for lead treatment Lupuzor with results expected in the first quarter of 2018. Lupuzor is anticipated to have blockbuster potential and is considered safer and more effective than GlaxoSmithKline’s (GSK) Benlysta. The drug treats lupus by modifying the behaviour of certain key cells involved in the development of the disease, which can be fatal as it causes the body to make antibodies that attack healthy tissue. Shares in ImmuPharma have nearly doubled in price this year to 97p as investors anticipate positive results from the study. More stocks with legs Pharmaceutical products developer Silence Therapeutics (SLN:AIM) has also had a good year thanks to moves in the RNAi sector, according to Simmonds. RNA is short for ribonucleic acid, which is a linear molecule that can play an important role in cells such as switching genes on and off. RNA interference (RNAi) is used to study gene function by enabling gene expression and targeting only problematic genes that cause the disease. Simmonds flags several catalysts behind Silence’s share price surge, including US listed Alnylam’s Phase III results for its patisiran to treat a rare nerve disorder and positive news on Spark Therapeutics’ therapy Luxturna. Shares in Quantum Pharma (QP.:AIM) have had a good run this year thanks to a takeover offer by Clinigen (CLIN:AIM). What news will continue to drive a strong performance? One of the key catalysts for any company working in the biopharma industry are trial readouts, specifically Phase III results. A strong outcome can lead to approval from healthcare authorities. These include the US Food and Drug Administration or European Medicines Agency. In the run up to results, investors tend to jump on the bandwagon and ride the share price momentum. There are several Phase III results expected in the next nine months, with some expected as early as the first quarter of 2018. These include ImmuPharma, Faron Pharmaceutical’s (FARN:AIM) Traumakine treatment for acute respiratory distress syndrome and Shield Therapeutics’ (STX:AIM) Feraccru for treating iron deficiency anaemia. In the first half of 2018, Phase III results are also anticipated from Diurnal (DNL:AIM) for its cortisol replace product Chronocort. (LMJ)
05/12/2017
14:05
money maker1: hamhamham you seem to have misunderstood the GSK HGSi deal and my valuation. GSK bought HGSi in 2012 for $3.6 billion, to get HGSi's 50% stake in their lupus drug Benlysta. That effectively valued 100% of Benlysta at $7.2 billion, or call it $7 billion because HGSi also had a few other drugs in the pipeline. £7 billion roughly equates to an IMM share price of £40. However the expectation is that IMM's Lupuzor will be more efficaceous and safer than Benlysta, making it worth more than Benlysta. In addition there is evidence Lupuzor should be able to treat several other high value indications, also making it worth more than Benlysta. Consequently I suggest a value for IMM, if Lupuzor passses Phase 3 for lupus and could be used in at least five other indications, of £60 to £100.
04/12/2017
15:44
hottingup: On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40. To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects, being cheaper to produce and more comfortable to administer, than Benlysta; use in other multiple indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications. Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40. N.B. Lupuzor™ Symposium 8th June 2016 - 3:35 pm 41 min 40 sec onwards - hTTps://player.vimeo.com/video/170358317 Data from IMM suggests Lupuzor / P140 may be able to treat several blockbuster autoimmune and non-autoimmune diseases, including: - Systemic Lupus Erythematosus (SLE) (Market size $4 bn) (SLE ends Phase 3, Q1 2018) - Neuropsychiatric lupus (NPSLE) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Rheumatoid Arthritis (Market size $28.5 bn by 2025) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022) - Guillan-Barre disease - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Asthma (Market size $20.7 bn in 2015) Other potential evaluations: - Scleroderma (Systemic Sclerosis, Raynaud) - Psoriasis - Multiple Sclerosis (MS) (Market size $20 bn by 2024) Negative preclinical results for potential re-evaluation: - Type I Diabetes (Market size $43 bn by 2021) - Amytrophic Lateral Sclerosis (ALS)
21/11/2017
10:14
hottingup: On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40. To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects, being cheaper to produce and more comfortable to administer, than Benlysta; use in other multiple indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications. Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40. N.B. Data from IMM suggests Lupuzor / P140 may be able to treat several blockbuster autoimmune and non-autoimmune diseases, including: - Systemic Lupus Erythematosus (SLE) (Market size $4 bn) - Neuropsychiatric lupus (NPSLE) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Rheumatoid Arthritis (Market size $28.5 bn by 2025) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022) - Guillan-Barre disease - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Asthma (Market size $20.7 bn in 2015) Other potential evaluations: - Scleroderma (Systemic Sclerosis, Raynaud) - Psoriasis - Multiple Sclerosis (MS) (Market size $20 bn by 2024) Negative preclinical results for potential re-evaluation: - Type I Diabetes (Market size $43 bn by 2021) - Amytrophic Lateral Sclerosis (ALS)
15/11/2017
11:59
hottingup: On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40. To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects, being cheaper to produce and more comfortable to administer, than Benlysta; use in other multiple indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications. Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40.
04/10/2017
06:07
wantonhearts: ("ImmuPharma" or the "Company") Completion of Lanstead Sharing Agreement ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company, wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L.P. ('Lanstead') in February 2016 ("Sharing Agreement"). As announced on 5 February 2016, Lanstead subscribed for £4.4 million of new ordinary shares in ImmuPharma, with both parties also entering into the Sharing Agreement. All 18 settlements of the Sharing Agreement have now been completed. Through both the subscription and Sharing Agreement, ImmuPharma has received a total of just over £5.0 million from Lanstead, with a net gain of £0.6 million more than originally subscribed. Tim McCarthy, Chairman of ImmuPharma, commented: "Lanstead has been an important supporter of ImmuPharma and we are delighted how effectively the Sharing Agreement has worked for both parties. We look forward to a continued supportive relationship with Lanstead as ImmuPharma seeks to create long term shareholder value within its asset portfolio and specifically our focus on hitting key milestones within our lead programme Lupuzor™, as we get nearer to reporting top-line Phase III results in Q1 2018." Nicholas Malins-Smith of Lanstead, commented: "We are delighted to have been able to be supportive in the progression of ImmuPharma's pivotal Phase III clinical trial of Lupuzor™. Through the Sharing Agreement with Lanstead, ImmuPharma has been able to benefit, through the increase in its share price, by securing additional funds over and above the original subscription amount. "Lanstead is pleased to remain a supportive shareholder of ImmuPharma and looks forward to the Company's further progress." This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
28/9/2017
14:39
waterloo01: This is the bit: THE SHARING AGREEMENT As part of the Subscription, the Company will enter into the Sharing Agreement, pursuant to which Immupharma will return an amount equal to 85 per cent. of the gross proceeds of the Subscription to Lanstead. The Sharing Agreement will enable the Company to share in any share price appreciation over the Benchmark Price (as defined below). However, if the Company's share price remains less than the Benchmark Price then the amount received by the Company under the Sharing Agreement will be less than the 85 per cent. of the gross proceeds of the Subscription which were pledged by the Company to Lanstead at the outset. The Sharing Agreement provides that the Company will receive 18 equal monthly settlement amounts as measured against a benchmark share price of 34.6667 pence per Ordinary Share (the "Benchmark Price"). The monthly settlement amounts for the Sharing Agreement are structured to commence two months following the admission to AIM of the Subscription Shares under the Sharing Agreement. If the measured share price (the "Measured Price"), calculated as the average volume weighted share price of the Company's Ordinary Shares over an agreed period prior to the monthly settlement date, exceeds the Benchmark Price, the Company will receive more than 100 per cent. of that monthly settlement due on a pro rata basis according to the excess of the Measured Price over the Benchmark Price. There is no upper limit placed on the additional proceeds receivable by the Company as part of the monthly settlements and the amount available in subsequent months is not affected. Should the Measured Price be below the Benchmark Price, the Company will receive less than 100 per cent. of the monthly settlement calculated on a pro rata basis and the Company will not be entitled to receive the shortfall at any later date. For example, if on a monthly settlement date the calculated Measured Price exceeds the Benchmark Price by 10 per cent., the settlement on that monthly settlement date will be 110 per cent. of the amount due from Lanstead on that date. If on the monthly settlement date the calculated Measured Price is below the Benchmark Price by 10 per cent., the settlement on the monthly settlement date will be 90 per cent. of the amount due on that date. Each settlement as so calculated will be in final settlement of Lanstead's obligation on that settlement date. Assuming the Measured Price equals the Benchmark Price on the date of each and every monthly settlement, Immupharma would receive aggregate proceeds of GBP4.43 million (before expenses) from the Subscription and Sharing Agreement, made up of the GBP0.66 million of the Subscription initially retained by the Company and 18 monthly settlements of approximately GBP0.21 million. The Company will pay Lanstead's legal costs incurred in the Subscription and in entering into the Sharing Agreement and, in addition, has agreed to issue to Lanstead 851,064 ordinary shares of 10 pence each in the Company (the "Value Payment Shares"). The issue of the 851,064 Value Payment Shares is, like the Subscription Shares, subject to approval at the General Meeting. In no event will fluctuations in the Company's share price result in any increase in the number of Subscription Shares issued by the Company or received by Lanstead. The Directors believe that a decline in the Company's share price would not result in any advantage accruing to Lanstead and the Sharing Agreement allows both Lanstead and the Company to benefit from future share price appreciation.
28/9/2017
12:44
carnivale: Luminoso and Flavio I take your points but acknowledging that punters perceive their modus operandi is a drag on the share price , does not mean that i agree with it or that they are right ... What is in their modus operandi that is bad or preventing people to buy ? i would argue the following Their modus operandi has saved IMM some funding cost (as the share price has risen above the ref price whilst securing IMM with funding at a time when there was not much demand Until we have proof of the contrary , they are still long of close to 7 MIL shares ...now that might scare a few people to think they need to hit the bid up to that amount , hence the reluctance of the share price to move ... But unless they have a standing order to sell the whole amount with brokers , ( in which case they would not need to report any breech of thresholds ) , they would need to report each 1% breach of threshold until they reached 3% , below which their duty to report any breach of threshold ceases ... The same goes for any institutional or individual shareholders ... if you have a Legal and General of this world suddenly selling some 1 mil of their 10 mil holding ( just an example) people would not fear forever their continued sale or blame L&G for a lacklustre share price performance ... Landstead should not be treated differently ...they are for all intents and purposes long of stock now, like any other shareholders ..their view or stance could change for a myriad of reasons , but they could well go into the results long of stock too ..... Anyway as Monty says , i do not worry about a few pence here or there as my belief is that (regardless of whether Landstead is the reson the share price has been slow to catch up or not) the 50 p levels will soon be but a distant memory
28/6/2017
09:25
sicilian_kan: There are 3 options: 1. A licensing deal for Lupuzor (lupus only), in a global or regional form. 2. A licensing deal for P140 (all autoimmune indications). 3. A buyout of the company. I think option 1 to be the most unlikely. Pharma would be much more comfortable taking options 2 or 3 for two reasons. First, just having a lupus drug will interfere with their pipelines. If they want an autoimmune pipeline, taking on a Lupus only license will either create a conflict with an existing pipeline or a future conflict if they are trying to build one. Second, taking on P140 or the company gives multiple possible hits. This derisks the purchase and enables the acquirer to not take the corporate or professional hit if, contrary to expectation, the first indication is unsuccessful. I think that option 2 is more likely that option 3. A buyout limits the upside to Immupharma, which we know the board do not want - they have high expectations and values on Lupuzor - and maximises the upfront exposure and risk for the pharma co acquiring. It would not be cheap. We have Zimmer for example continuing to invest and buying >£700k of shares since the recent Phase 3 launch etc. The board know the value of Lupuzor and P140. Heck, even nobby is saying we are significantly undervalued at present. Unless a very large sum was paid, I cannot see a buyout being an option, unless of course the remainder of the pipeline is also of interest to the acquirer, e.g. diabetes etc. There remains a possibility, but I think option 2 to be more likely. So we are looking at a potential licensing deal P140. I don't doubt that a deal could be struck. The question as ever is the price. Up front and royalty % in particular being the most important. What we do know is that the board are keen on the pipeline and the potential for P140. We also know Zimmer likes to keep a large % holding in Immupharma. The last thing I think the board would want to risk Lupuzor missing its targets (however confident they are in the trial succeeding) because if Lupuzor fails the lupus trial, then how are they going to raise funds thereafter for e.g. RA? Particularly given the funding took a while to arrange for Lupuzor. Do they really want to risk losing everything (RA, Crohn's, diabetes, ophthalmic etc) when they clearly have great belief in the pipeline, all for a punt on Lupuzor, particularly when the rewards in RA are immense and dwarf the rewards for lupus, which are potentially blockbuster in themselves? In short, I think it would be foolhardy for the board to risk going it alone at this stage given the potential in other indications. Not only this, but we know the board want to negotiate a deal too. They have even stated in the very recent Annual Report that they are in negotiations: "The Company raised the funds [£4.1m in March 2017 - sk] in order to further strengthen the Company’s Statement of Financial Position as negotiations continue with potential partners for Lupuzor™ and to support further investment in ImmuPharma’s earlier stage portfolio." I'm hoping for something in the region of close to $100m up front with 17-20% royalties on Lupuzor with the remaining P140 indications potentially having 13-15% royalties. The up front fee is a drop in the ocean for even mid sized pharma, particularly if acquiring the majority of a late stage Phase 3 drug with imminent results and a potential autoimmune platform in RA etc. I'm sure a deal can be struck and it should be lucrative and transformative for the company and its share price. I think that what makes it likely and different to last time is the potential autoimmune platform. But as ever, this is out of our hands and it remains just a possibility. I may be wrong. That said, I am holding because I believe that this must surely be in everyone's best interests and because I think a deal can be done. I also believe the company is massively undervalued and that any deal will send the IMM shareprice into the relative stratosphere. First stop the broker target of 171p on a deal?
Immupharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171217 08:06:45